OCA
GILD icon

OpenArc Corporate Advisory’s Gilead Sciences GILD Stock Holding History

OpenArc Corporate Advisory’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.86M Buy
46,394
+945
+2% +$125K 0.07% 145
2026
Q1 		$6.33M Buy
45,449
+976
+2% +$137K 0.09% 135
2025
Q4 		$5.46M Buy
+44,473
New +$5.4M 0.09% 133

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OpenArc Corporate Advisory's GILD Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its Gilead Sciences (GILD) stake by 2.1% in Q2 2026, buying an estimated $125K and bringing the position to 46,394 shares worth $5.86M. The position accounts for 0.07% of the portfolio, ranked #145.

OpenArc Corporate Advisory first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.33M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • OpenArc Corporate Advisory held 46,394 shares of Gilead Sciences worth $5.86M as of Q2 2026.
  • OpenArc Corporate Advisory bought 945 Gilead Sciences shares in Q2 2026, an estimated $125K.
  • Gilead Sciences made up 0.07% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #145 holding.
  • OpenArc Corporate Advisory first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • OpenArc Corporate Advisory's Gilead Sciences position peaked at $6.33M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.